Scribe Therapeutics, Inc. Listed Primary

What the company does

Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic diseases, with initial programs targeting atherosclerotic cardiovascular disease (ASCVD). Its lead product candidate, STX-1150, uses its proprietary ELXR epigenetic silencing technology to deliver persistent and potent LDL-C reductions without permanent genetic changes, and the company has initiated a first-in-human clinical trial of STX-1150 in Australia. Scribe applies a full-stack engineering approach it calls CRISPR by Design, coupling generative AI/ML with parallel experimental validation, and is advancing two additional in vivo product candidates (STX-1200 and STX-1400) targeting additional lipid drivers of ASCVD.

Use of proceeds

The company estimates net proceeds from the offering and concurrent private placement will be approximately $122.8 million (or approximately $140.7 million if the underwriters exercise their option in full), based on the $15.00 initial public offering price. It intends to use the net proceeds, together with existing cash and cash equivalents, to advance the development of its lead product candidate STX-1150, to advance STX-1400 and STX-1200, for continued advancement of its pipeline, partnered programs, CRISPR-based technologies (including XE and ELXR) and next-generation gene editing technologies, and for working capital and other general corporate purposes.

Underwriters

Extracted from 424B4 0001193125-26-316503, filed Jul 27, 2026 and verified against that filing text.

Key risk factors

• Pre-clinical/early clinical stage with no approved products

  “We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.”

• Competition in rapid technological change

  “We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are more effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.”

• Concentration of stock ownership

  “Our principal stockholders and management own a significant percentage of our common stock and will be able to control matters subject to stockholder approval.”

• No dividend payments

  “We do not currently intend to pay dividends on our common stock and, consequently, our stockholders' ability to achieve a return on their investment will depend on appreciation of the value of our common stock.”

• Emerging growth company / smaller reporting company status

  “We are an "emerging growth company" and a "smaller reporting company" and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors.”

• Natural disasters and business continuity risk

  “We or the third parties we depend on may be adversely affected by natural disasters, terrorist activity, pandemics and other events beyond our control, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.”

• Use of proceeds risk

  “Pending their use, we may invest the net proceeds from this offering and the concurrent private placement in a manner that does not produce income or that loses value.”